News provided by Ro Apr 02, 2026, 13:02 ET The most effective GLP-1 medication is now available in a multi-dose pen NEW YORK, April 2, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound (tirzepatide) KwikPen nationwide on its platform
Within the data, the investigators identified 100 288 individuals diagnosed with Type 2 diabetes who had been prescribed standard diabetes therapies (glitazones, GLP-1R agonists, and/or dipeptidyl peptidase 4 (DPP-4) inhibitors) on or after the 1st January 2006
doi: 10.5114/ada.2024.138818
The table below summarizes the key findings from the study and supporting evidence
It is one of several second-generation triptans under development for the treatment of migraine